FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2371508518> ?p ?o ?g. }

• W2371508518 endingPage "1400" @default.
• W2371508518 startingPage "1394" @default.
• W2371508518 abstract "This study aimed to determine the safety and effectiveness of bevacizumab (B) plus FOLFOX or CAPOX in advanced neuroendocrine tumors (NETs) by performing a combined analysis of 2 separate prospective phase II studies.In the FOLFOX/B study, patients received chemotherapy without scheduled breaks in 3 cohorts: carcinoid, pancreatic NET, and poorly differentiated neuroendocrine carcinomas. In the CAPOX/B study, NET subtypes were pooled, and patients were treated with 4 cycles of CAPOX/B followed by optional maintenance therapy. Primary end points were radiographic response rate (RR) after 12 cycles (FOLFOX/B), progression-free survival (PFS) (CAPOX/B), and toxicity (both).Seventy-six patients (FOLFOX/B, n = 36; CAPOX/B, n = 40) were included. In FOLFOX/B, RR for carcinoid at 12 cycles 3/22 (13.6%), median PFS 19.3 months; RR for pancreatic NET at 12 cycles 4/12 (41.7%), median PFS 21 months; RR 1/2 (50%) in poorly differentiated neuroendocrine carcinoma; pooled RR 25% and median PFS 21 months (1-year PFS 68%). In CAPOX/B (pooled NET), RR 18% and median PFS 16.7 months (1-year PFS 65%). Predictable toxicity was observed.Neither study met its primary end point, but radiographic responses and prolonged disease stability in previously progressing patients suggest that selected patients with NET may benefit from oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab and that the combination may warrant further study." @default.
• W2371508518 created "2016-06-24" @default.
• W2371508518 creator A5000401547 @default.
• W2371508518 creator A5030715815 @default.
• W2371508518 creator A5033960518 @default.
• W2371508518 creator A5036188351 @default.
• W2371508518 creator A5037875642 @default.
• W2371508518 creator A5040325455 @default.
• W2371508518 creator A5042806301 @default.
• W2371508518 creator A5070411005 @default.
• W2371508518 creator A5072641295 @default.
• W2371508518 creator A5074479466 @default.
• W2371508518 creator A5081606866 @default.
• W2371508518 date "2016-11-01" @default.
• W2371508518 modified "2023-09-24" @default.
• W2371508518 title "Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors" @default.
• W2371508518 cites W1771569409 @default.
• W2371508518 cites W1974459801 @default.
• W2371508518 cites W1981584797 @default.
• W2371508518 cites W2005250386 @default.
• W2371508518 cites W2024966748 @default.
• W2371508518 cites W2027176779 @default.
• W2371508518 cites W2042265119 @default.
• W2371508518 cites W2050942858 @default.
• W2371508518 cites W2057103712 @default.
• W2371508518 cites W2085705101 @default.
• W2371508518 cites W2090232354 @default.
• W2371508518 cites W2107276199 @default.
• W2371508518 cites W2115686439 @default.
• W2371508518 cites W2118672029 @default.
• W2371508518 cites W2123731993 @default.
• W2371508518 cites W2125447919 @default.
• W2371508518 cites W2128879260 @default.
• W2371508518 cites W2130735070 @default.
• W2371508518 cites W2135657152 @default.
• W2371508518 cites W2137142564 @default.
• W2371508518 cites W2139248078 @default.
• W2371508518 cites W2143743735 @default.
• W2371508518 cites W2158247064 @default.
• W2371508518 cites W2158474413 @default.
• W2371508518 cites W2166100060 @default.
• W2371508518 cites W2339290868 @default.
• W2371508518 doi "https://doi.org/10.1097/mpa.0000000000000659" @default.
• W2371508518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27171514" @default.
• W2371508518 hasPublicationYear "2016" @default.
• W2371508518 type Work @default.
• W2371508518 sameAs 2371508518 @default.
• W2371508518 citedByCount "51" @default.
• W2371508518 countsByYear W23715085182016 @default.
• W2371508518 countsByYear W23715085182017 @default.
• W2371508518 countsByYear W23715085182018 @default.
• W2371508518 countsByYear W23715085182019 @default.
• W2371508518 countsByYear W23715085182020 @default.
• W2371508518 countsByYear W23715085182021 @default.
• W2371508518 countsByYear W23715085182022 @default.
• W2371508518 countsByYear W23715085182023 @default.
• W2371508518 crossrefType "journal-article" @default.
• W2371508518 hasAuthorship W2371508518A5000401547 @default.
• W2371508518 hasAuthorship W2371508518A5030715815 @default.
• W2371508518 hasAuthorship W2371508518A5033960518 @default.
• W2371508518 hasAuthorship W2371508518A5036188351 @default.
• W2371508518 hasAuthorship W2371508518A5037875642 @default.
• W2371508518 hasAuthorship W2371508518A5040325455 @default.
• W2371508518 hasAuthorship W2371508518A5042806301 @default.
• W2371508518 hasAuthorship W2371508518A5070411005 @default.
• W2371508518 hasAuthorship W2371508518A5072641295 @default.
• W2371508518 hasAuthorship W2371508518A5074479466 @default.
• W2371508518 hasAuthorship W2371508518A5081606866 @default.
• W2371508518 hasConcept C121608353 @default.
• W2371508518 hasConcept C126322002 @default.
• W2371508518 hasConcept C141071460 @default.
• W2371508518 hasConcept C143998085 @default.
• W2371508518 hasConcept C168563851 @default.
• W2371508518 hasConcept C203092338 @default.
• W2371508518 hasConcept C2776694085 @default.
• W2371508518 hasConcept C2777802072 @default.
• W2371508518 hasConcept C2778260052 @default.
• W2371508518 hasConcept C2779066768 @default.
• W2371508518 hasConcept C2780962732 @default.
• W2371508518 hasConcept C526805850 @default.
• W2371508518 hasConcept C71924100 @default.
• W2371508518 hasConcept C90924648 @default.
• W2371508518 hasConceptScore W2371508518C121608353 @default.
• W2371508518 hasConceptScore W2371508518C126322002 @default.
• W2371508518 hasConceptScore W2371508518C141071460 @default.
• W2371508518 hasConceptScore W2371508518C143998085 @default.
• W2371508518 hasConceptScore W2371508518C168563851 @default.
• W2371508518 hasConceptScore W2371508518C203092338 @default.
• W2371508518 hasConceptScore W2371508518C2776694085 @default.
• W2371508518 hasConceptScore W2371508518C2777802072 @default.
• W2371508518 hasConceptScore W2371508518C2778260052 @default.
• W2371508518 hasConceptScore W2371508518C2779066768 @default.
• W2371508518 hasConceptScore W2371508518C2780962732 @default.
• W2371508518 hasConceptScore W2371508518C526805850 @default.
• W2371508518 hasConceptScore W2371508518C71924100 @default.
• W2371508518 hasConceptScore W2371508518C90924648 @default.
• W2371508518 hasIssue "10" @default.
• W2371508518 hasLocation W23715085181 @default.

• next